ReviewCureus2026
Glucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expanding use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs for obesity and type 2 diabetes has important implications for reproductive-aged patients. As these medications are increasingly prescribed before conception and after delivery, obstetrician-gynecologists need practical guidance on contraception, pregnancy planning, inadvertent pregnancy exposure, medication discontinuation, gestational weight trajectory, postpartum use, and lactation. This narrative review synthesizes current evidence on GLP-1 RA and dual GIP/GLP-1 RA use across the reproductive spectrum, including mechanisms relevant to ovulation and polycystic ovary syndrome (PCOS), pharmacokinetic interactions with oral hormonal contraceptives, animal and human pregnancy safety data, preconception washout recommendations, management after inadvertent early-pregnancy exposure, postpartum prescribing, breastfeeding considerations, and unresolved research gaps. Available evidence suggests potential reproductive benefits in some patients with metabolic dysfunction or PCOS, but current pregnancy and lactation data remain limited. Until stronger prospective safety data are available, counseling should be individualized, agent-specific, and centered on pregnancy intention, contraceptive reliability, metabolic risk, and shared decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.